Patient characteristics
| NAT-group (t3–t4) | IFN1-subgroup (t1–t3)* | IFN2-subgroup (t1–t2)* | PML | |
|---|---|---|---|---|
| Total n | 839 | 414 | 170 | 5 |
| Female n (%) | 587 (70) | 280 (68) | 106 (62) | 3 (60) |
| Median age (range) | 36 (12–63) | 37 (16–63) | 37 (16–58) | 37 (27–44) |
| Median Δt months (range)† | 12 (1–38) | 21 (1–70) | 13 (1–59) | 25 (18–49) |
| Persistent positives n (% of all) | 426 (51) | 202 (49) | 83 (49) | |
| Female n (%) | 278 (65) | 123 (61) | 47 (57) | |
| Median age (range) | 38 (13–63) | 39 (16–63) | 38 (16–58) | |
| Median Δt months (range)† | 12 (1–38) | 21 (1–70) | 12 (1–40) | |
| Persistent negatives n (% of all) | 330 (39) | 172 (42) | 75 (44) | |
| Female n (%) | 245 (74) | 127 (74) | 53 (71) | |
| Median age (range) | 35 (12–58) | 35 (17–58) | 35 (20–54) | |
| Median Δt months (range)† | 12 (1–38) | 19 (1–69) | 13 (2–59) | |
| Seroreverters n (% of all) | 45 (5) | 8 (2) | 8 (5) | |
| Female n (%) | 36 (80) | 4 (50) | 4 (50) | |
| Median age (range) | 34 (14–60) | 31 (22–45) | 39 (28–45) | |
| Median Δt months (range)† | 23 (1–31) | 22 (2–46) | 20 (3–43) | |
| Sero-converters n (% of all) | 38 (5) | 32 (8) | 4 (2) | |
| Female n (%) | 28 (74) | 26 (81) | 2 (50) | |
| Median age (range) | 35 (20–53) | 35 (18–53) | 33 (25–39) | |
| Median Δt months (range)† | 24 (2–37) | 25 (1–52) | 11 (1–39) |
*IFN1- and IFN2-subgroups are subgroups of the NAT-group defined by samples available prior to NAT therapy at t1 and t2. For details see online supplementary efigure S1.
†Δt months=time between first and last sample.
NAT, Natalizumab; PML, progressive multifocal leukoencephalopathy.